Glucose B. Braun

Glucose B. Braun is an intravenous solution that contains glucose monohydrate as its active ingredient; the product’s strength is not specified in the available labeling, and it is supplied as a sterile liquid for parenteral administration. Marketed in the European Union, this preparation is classified as an excipient/solvent and is used as an energy source in clinical settings such as parenteral nutrition and hypoglycemia management.

Glucose B. Braun is employed in several clinical situations where rapid provision of carbohydrate calories or correction of low blood glucose is required.

- Treatment of hypoglycemia in patients unable to take oral glucose. - Component of parenteral nutrition regimens to supply energy. - Fluid and electrolyte replacement when combined with appropriate electrolytes. - Dilution medium for intravenous drug admixtures that require a carbohydrate carrier. - Support during perioperative fasting to maintain blood glucose levels.

Adverse reactions to Glucose B. Braun are generally related to the intravenous administration of a carbohydrate solution and may vary in frequency and severity.

Common: - Local irritation or pain at the infusion site. - Mild hyperglycemia when large volumes are infused rapidly. - Electrolyte shifts such as mild hyponatremia or hypokalemia. - Nausea or vomiting associated with rapid infusion.

Serious: - Severe hyperglycemia leading to osmotic diuresis. - Fluid overload causing pulmonary edema in susceptible patients. - Allergic reactions ranging from urticaria to anaphylaxis. - Hyperosmolar hyperglycemic state in patients with uncontrolled diabetes.

When using Glucose B. Braun, clinicians should assess patient-specific factors and monitor parameters to minimize potential complications.

- Verify blood glucose levels before and during infusion to avoid excessive hyperglycemia. - Adjust infusion rate in patients with renal or cardiac insufficiency to prevent fluid overload. - Use compatible electrolyte solutions and avoid mixing with incompatible drugs. - Monitor serum electrolytes, especially sodium and potassium, during prolonged therapy. - Consider alternative carbohydrate sources in patients with known glucose intolerance or severe diabetes. - Ensure aseptic technique to reduce risk of catheter‑related infection.

Glucose B. Braun may interact with other intravenous agents or systemic medications, influencing glucose balance, electrolyte status, or solution compatibility.

Avoid: - Co‑administration with high‑dose insulin infusions without close glucose monitoring. - Mixing with calcium‑containing solutions that can precipitate calcium gluconate. - Simultaneous infusion of potassium chloride in concentrations exceeding recommended limits.

Use with caution: - Concurrent use of diuretics that may alter fluid and electrolyte balance. - Administration alongside beta‑adrenergic agonists, which can increase glucose production. - Use with nephrotoxic drugs in patients at risk for renal impairment. - Combining with other hypertonic solutions; monitor osmolar load.